Most importantly, genetic and pharmacologic inhibition of the GSK3B-53BP1 signaling axis dramatically enhances the cytotoxic response of cancer in vitro and in vivo to PARP inhibitors (PARPi) independent of BRCA1 status. Here, GSK3B is linked to cancer.